We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
Stockal+Disclaimer.pdf
19 own
31 watching
Current Price
$0.39
$-0.01
(-2.23%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
88.84M
52-Week High
1.09
52-Week Low
0.3601
Average Volume
0.56M
Dividend Yield
--
P/E Ratio
--
Market Capitalization88.84M
52-Week High1.09
52-Week Low0.3601
Average Volume0.56M
Dividend Yield--
P/E Ratio--
What does the Stockal+Disclaimer.pdf do?
DURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and drug delivery programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for experimental research in mice, rats, and other laboratory animals; and a range of biodegradable polymers for use as raw materials for pharmaceutical and medical devices under the LACTEL brand. Its product pipeline consists of multiple investigational drug candidates in clinical development, such as DUR-928, an endogenous, orally bioavailable small molecule that is in Phase 1 development stage to play a regulatory role in lipid homeostasis, inflammation, and cell survival. The company's advanced oral, injectable, and transdermal delivery technologies are designed to enable new indications and enhanced attributes for small-molecule and biologic drugs, including POSIMIR, an investigational analgesic product intended to deliver bupivacaine to provide up to 3 days of pain relief after surgery; and REMOXY ER, an investigational extended release pain relief drug. DURECT Corporation markets and sells its ALZET and LACTEL product lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has collaboration agreements with Santen Pharmaceutical Co., Ltd.; Impax Laboratories, Inc.; Zogenix, Inc.; and Pain Therapeutics, Inc. DURECT Corporation was founded in 1998 and is headquartered in Cupertino, California.
Read More
How much money does Stockal+Disclaimer.pdf make?
News & Events about Stockal+Disclaimer.pdf.
PR Newswire
1month ago
DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2 DURECT Corporation to Announce Third Quarter 2022 Financial Results and Provide Business Update on November 2 PR Newswire CUPERTINO, Calif., Oct. 26, 2022 CUPERTINO, Calif., Oct. 26, 2022...
PR Newswire
2 months ago
DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial DURECT Reaches Enrollment Milestone in Phase 2b AHFIRM Trial PR Newswire CUPERTINO, Calif., Oct. 6, 2022 AHFIRM enrollment surpasses 200 of the planned 300 AH patients Enrollment completion now anticipated in Q2 2023CUPERTINO, Calif...
PR Newswire
2 months ago
Innocoll and DURECT Announce U.S. launch of POSIMIR Innocoll and DURECT Announce U.S. launch of POSIMIR PR Newswire ATHLONE, Ireland and CUPERTINO, Calif., Sept. 26, 2022 POSIMIR is now commercially available in the U.S. for the treatment of post-surgical pain in adults following arthroscopic...
PR Newswire
5 months ago
DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer DURECT Corporation Appoints Timothy M. Papp as Chief Financial Officer PR Newswire CUPERTINO, Calif., July 5, 2022 CUPERTINO, Calif., July 5, 2022 /PRNewswire/ --DURECT Corporation(Nasdaq: DRRX), a biopharmaceutical company...
PR Newswire
6 months ago
DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference DURECT Corporation to Present at the H.C. Wainwright Global Investment Conference PR Newswire CUPERTINO, Calif., May 18, 2022 CUPERTINO, Calif., May 18, 2022 /PRNewswire/ -- DURECT Corporation (Nasdaq: DRRX) today...
Frequently Asked Questions
Frequently Asked Questions
What is Stockal+Disclaimer.pdf share price today?
plus_minus_icon
Can Indians buy Stockal+Disclaimer.pdf shares?
plus_minus_icon
How can I buy Stockal+Disclaimer.pdf shares from India?
plus_minus_icon
Can Fractional shares of Stockal+Disclaimer.pdf be purchased?
plus_minus_icon
What are the documents required to start investing in Stockal+Disclaimer.pdf stocks?
plus_minus_icon
What is today’s traded volume of Stockal+Disclaimer.pdf?
plus_minus_icon
What is today’s market capitalisation of Stockal+Disclaimer.pdf?
plus_minus_icon
What is the 52-Week High and Low Range of Stockal+Disclaimer.pdf?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf down from its 52-Week High?
plus_minus_icon
What percentage is Stockal+Disclaimer.pdf up from its 52-Week Low?
plus_minus_icon
Current Price
$0.39
$-0.01
(-2.23%)
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Get Started with as little as $1.00